One week of strong sugar control and full "heart" benefit, smegaglutide injection Novotai® was approved in China

Recently, the State Drug Administration (NMPA) approved the Connaught Novo Nordisk R & D and production of Thai ^® (US Secretary Grew peptide injection) listing application in China
.

Novo Thai ^® (US Secretary Grew peptide injection) before China formally approved, because of its series of clinical studies show efficacy and excellent benefits, get attention, and once said that "Suo Malu peptide" temporary use The name has been continuously reported by the media and is highly anticipated by the industry
.

As a heavy week of GLP-1 administered products, Novo Thai ^® to breakthrough technology will extend the half-life of up to 7 days to achieve administered once a week potent sugar control, precise standards, and benefit from a comprehensive cardiometabolic , To provide more effective, simple and safe treatment options for Chinese patients with type 2 diabetes

The high incidence of complications affects the quality of life of Chinese sugar friends

The number of diabetic patients in China exceeds 129.
8 million ^[1] , of which only 15.
8% have achieved blood glucose control standards ^[2]
.

Diabetes is prone to cause macrovascular disease, microvascular disease and other complications, which seriously affects the quality of life of patients and increases the burden of disease

In recent years, GLP-1 receptor agonists (GLP-1 RA), which have significant hypoglycemic effects and multiple benefits, have gradually increased their status in major guidelines
.

Domestic and foreign guidelines have consistently clarified the important therapeutic status of GLP-1 RA for patients with type 2 diabetes with cardiovascular disease or high cardiovascular risk

Professor Mu Yiming, Director of the Department of Endocrinology, General Hospital of the People’s Liberation Army, said: “The harm of diabetes is not only the disease itself, but also a series of serious complications that diabetes may bring
.

As the prevalence of diabetes in China is increasing year by year, attention is paid to accurate blood glucose standards.

Taking into account both potent hypoglycemic and comprehensive cardiovascular metabolic benefits, escort patients to live peacefully

Novo Thai ^® led Chinese experts registered clinical research, Professor JI Li-nong People's Hospital of Peking University, director of endocrinology, said: "As Novo Thai ^® Chinese clinical research investigators, that Novo Thai ^® in China approved after the news very happy
.

Novo Thai ^® is a highly anticipated hypoglycemic agents injected into the human body a drug effect may last for seven days, is a GLP-1 RA in blood sugar control standard rate of current drugs already on the market

       The SUSTAIN series of large-scale multi-center clinical studies around the world enrolled more than 11,000 patients, including 605 Chinese patients, and confirmed the excellent hypoglycemic efficacy, safety and cardiovascular and metabolic benefits of simeglutide
.

The results of the SUSTAIN China study ^[6] showed that in the Chinese population, smeglutide can significantly reduce glycosylated hemoglobin (HbA1c), the highest reduction is 1.
8%, the HbA1c compliance rate (<7.
0%) is as high as 86.

       In addition, simeglutide can also improve a number of cardiovascular metabolic indicators, and better comprehensively manage a variety of cardiovascular risk factors including weight, blood pressure and blood lipids
.

The results of the SUSTAIN 6 study ^[7] showed that on the basis of standard treatment, smeglutide significantly reduced the risk of major cardiovascular adverse events (MACE) by 26% and significantly reduced the risk of non-fatal stroke by 39% compared with placebo.

       Both potent, long-lasting and multi-effect of Novo Thai ^® , will not only boost blood sugar stable and effective compliance, and a comprehensive metabolic cardiovascular benefit to help patients achieve long-term protection, a substantial increase medication compliance in patients, improve patient survival Quality helps patients return to life in peace
.

Zhang Kezhou, Corporate Vice President of Novo Nordisk's Pharmaceutical and Quality Department in China, said: "Diabetes is a complex and lifelong disease

       Zhou Xiaping, Senior Vice President and President of Greater China of Novo Nordisk, said: “This year marks the 100th anniversary of the discovery of insulin by humans
.
For nearly a century, as a global leader in diabetes treatment, Novo Nordisk has always been patient-centric and focused.
To change diabetes, lead the innovation of insulin drugs and injection devices, and promote the development of disease awareness and management concepts
.
Focusing on the unmet medical needs of patients, we are also determined to innovate in the field of GLP-1 treatment and continue to lead breakthroughs
.
Thanks to National Pharmaceuticals Administration and relevant departments to accelerate the introduction of innovative drugs in China strong support and guidance, thanks to the contribution of researchers and participation in clinical trials of subjects! Novo Thai ^® this blockbuster new products approved, will further strengthen us in China’s diabetes treatment product portfolio provides medical professionals and patients with more abundant treatment options
.
In the future, we will continue to uphold our mission to contribute to the change of diabetes in China and help achieve the goals of the
“ Healthy China 2030” plan .
"

       About Novo Thai ^® (US Secretary Grew peptide injection)

       Novo Thai ^® (US Secretary Grew peptide injection) is Novo Nordisk a new long-acting glucagon-like peptide -1 (GLP-1) analogue, is now in the United States, Europe, Canada, Japan Approved for listing in 52 countries and regions
.

       Novo Tai ^® half-life of 7 days, for weekly injections and stable blood concentration
.
SUSTAIN series of studies have shown that, whether single application or in combination with other oral hypoglycemic agents or basal insulin, Novo Thai ^® could significantly reduce glycosylated hemoglobin (HbA1c), the maximum decrease of 1.
8%, hypoglycemic effect was significantly better than placebo West Gliptin, canagliflozin, dulaglutide, liraglutide, exenatide weekly preparations and insulin glargine and other hypoglycemic drugs
.
Registration clinical studies in China, Novo Thai ^® in the Chinese population HbA1c compliance rate as high as 86.
1%, showing good hypoglycemic effect
.
Meanwhile, SUSTAIN 6 studies have shown promise and Thailand ^® can significantly reduce the risk of MACE in patients with type 2 diabetes by 26% and significantly improve patients' weight, blood pressure, lipids and many other indicators, for the benefit of patients bring comprehensive cardiovascular metabolic
.

       In January 2020, Novo Thai ^® cardiovascular indications received US FDA approval for reducing the risk of major cardiovascular events in patients with type 2 diabetes in adults with cardiovascular disease
.

       About Novo Nordisk

       Founded in 1923, Novo Nordisk is a global biopharmaceutical company headquartered in Denmark
.
Our goal is to promote change, to combat diabetes and obesity, a rare blood disease, endocrine disorders and other serious chronic diseases
.
To achieve this goal, we lead scientific breakthroughs, expand the company's drug availability, and are committed to preventing and ultimately curing diseases
.
Novo Nordisk has approximately 45,300 employees in 80 countries and regions around the world, and provides products and services to 169 countries and regions around the world
.

 

       1.
Yongze Li, et al.
BMJ.
2020, 369:m997.

       2.
Wang L, et al.
JAMA.
2017, 317(24):2515-2523.

       3.
Diabetes Branch of Chinese Medical Association, China Type 2 Diabetes Prevention and Treatment Guidelines (2017 Edition)

       4.
Hong Tianpei.
, et al.
CAPTURE.
GW-ICC 2020 Poster: GW31 –e1199.

       5.
Mosenzon O, Alguwaihes A, Arenas Leon JL, et al.
CAPTURE Abstract 158.
Presented at the 56th Annual Meeting of the European Association of the Study of Diabetes, Macrovascular complications and beyond, 10:15 CDT on 24 September 2020.

       6.
Linong Ji, et al.
Diabetes Obes Metab.
2020 Oct 19.
doi: 10.
1111/dom.
14232.
Online ahead of print.

       7.
Marso SP, et al.
NEJM 2016; 375(19) 1834-1844.